Leukocyte immunoglobulin-like receptor 1-expressing human natural killer cell subsets differentially recognize isolates of human cytomegalovirus through the viral major histocompatibility complex class I homolog UL18

Journal of Virology

Volumn 90, Issue 6, 2016, Pages 3123-3137

  Chen, Kevin C ^a   Stanton, Richard J ^b   Banat, Jareer J ^c   Wills, Mark R ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b Cardiff Institute of Infection and Immunity   (United Kingdom)

^c ALTNAGELVIN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LEUKOCYTE IMMUNOGLOBULIN LIKE RECEPTOR 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MEMBRANE RECEPTOR; NATURAL KILLER CELL RECEPTOR; NKG2C PROTEIN; UL18 PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN; CAPSID PROTEIN; IMMUNOGLOBULIN RECEPTOR; LEUKOCYTE ANTIGEN; LILRB1 PROTEIN, HUMAN; VP23 PROTEIN, HUMAN HERPESVIRUS 1;

ARTICLE; CELL ASSAY; CELL EXPANSION; CONTROLLED STUDY; CYTOMEGALOVIRUS; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; MOLECULAR DYNAMICS; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEQUENCE ANALYSIS; VIROGENESIS; VIRUS ISOLATION; VIRUS STRAIN; CHEMISTRY; IMMUNOLOGY; LYMPHOCYTE SUBPOPULATION; MAJOR HISTOCOMPATIBILITY COMPLEX; METABOLISM;

ANTIGENS, CD; CAPSID PROTEINS; CYTOMEGALOVIRUS; HUMANS; KILLER CELLS, NATURAL; LYMPHOCYTE SUBSETS; MAJOR HISTOCOMPATIBILITY COMPLEX; RECEPTORS, IMMUNOLOGIC;

EID: 84961151732     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02614-15     Document Type: Article

References (69)

1. Snydman DR, Werner BG, Heinze-Lacey B, Berardi VP, Tilney NL, Kirkman RL, Milford EL, Cho SI, Bush HL, Jr, Levey AS, Strom TB, Carpenter CB, Levey RH, Harmon WE, Zimmerman CE, II, Shapiro ME, Steinman T, LoGerfo F, Idelson B, Schröter GPJ, Levin MJ, McIver J, Leszczynski J, Grady GF. 1987. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. N Engl J Med 317:1049-1054. http://dx.doi.org/10.1056/NEJM198 710223171703.
2. Macagno A, Bernasconi NL, Vanzetta F, Dander E, Sarasini A, Revello MG, Gerna G, Sallusto F, Lanzavecchia A. 2010. Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex. J Virol 84:1005-1013. http://dx.doi.org/10.1128/JVI.01809-09.
3. Boehme KW, Guerrero M, Compton T. 2006. Human cytomegalovirus envelope glycoproteins B andHare necessary for TLR2 activation in permissive cells. J Immunol 177:7094-7102. http://dx.doi.org/10.4049/jimmunol.177.10.7094.
4. Bodaghi B, Jones TR, Zipeto D, Vita C, Sun L, Laurent L, Arenzana-Seisdedos F, Virelizier JL, Michelson S. 1998. Chemokine sequestration by viral chemoreceptors as a novel viral escape strategy: withdrawal of chemokines from the environment of cytomegalovirus-infected cells. J Exp Med 188:855-866. http://dx.doi.org/10.1084/jem.188.5.855.
5. Sylwester AW, Mitchell BL, Edgar JB, Taormina C, Pelte C, Ruchti F, Sleath PR, Grabstein KH, Hosken NA, Kern F, Nelson JA, Picker LJ. 2005. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med 202:673-685. http://dx.doi.org/10.1084/jem.20050882.
6. Day EK, Carmichael AJ, ten Berge IJ, Waller EC, Sissons JG, Wills MR. 2007. Rapid CD8+ T cell repertoire focusing and selection of high-affinity clones into memory following primary infection with a persistent human virus: human cytomegalovirus. J Immunol 179:3203-3213. http://dx.doi.org/10.4049/jimmunol.179.5.3203.
7. Jackson SE, Mason GM, Wills MR. 2011. Human cytomegalovirus immunity and immune evasion. Virus Res 157:151-160. http://dx.doi.org/10.1016/j.virusres.2010.10.031.
8. Sinclair J. 2008. Human cytomegalovirus: latency and reactivation in the myeloid lineage. J Clin Virol 41:180-185. http://dx.doi.org/10.1016/j.jcv.2007.11.014.
9. Taylor-Wiedeman J, Sissons JG, Borysiewicz LK, Sinclair JH. 1991. Monocytes are a major site of persistence of human cytomegalovirus in peripheral blood mononuclear cells. J Gen Virol 72(Part 9):2059-2064.
10. Crough T, Khanna R. 2009. Immunobiology of human cytomegalovirus: from bench to bedside. Clin Microbiol Rev 22:76-98. http://dx.doi.org/10.1128/CMR.00034-08.
11. Sissons JG, Carmichael AJ. 2002. Clinical aspects and management of cytomegalovirus infection. J Infect 44:78-83. http://dx.doi.org/10.1053/jinf.2001.0949.
12. Ho M. 2008. The history of cytomegalovirus and its diseases. Med Microbiol Immunol 197:65-73. http://dx.doi.org/10.1007/s00430-007-0066-x.
13. Kotton CN. 2010. Management of cytomegalovirus infection in solid organ transplantation. Nat Rev Nephrol 6:711-721. http://dx.doi.org/10.1038/nrneph.2010.141.
14. Stagno S, Pass RF, Cloud G, Britt WJ, Henderson RE, Walton PD, Veren DA, Page F, Alford CA. 1986. Primary cytomegalovirus infection in pregnancy. Incidence, transmission to fetus, and clinical outcome. JAMA 256:1904-1908.
15. Kondo M, Weissman IL, Akashi K. 1997. Identification of clonogenic common lymphoid progenitors in mouse bone marrow. Cell 91:661-672. http://dx.doi.org/10.1016/S0092-8674(00)80453-5.
16. Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, Yokoyama WM, Ugolini S. 2011. Innate or adaptive immunity? The example of natural killer cells. Science 331:44-49. http://dx.doi.org/10.1126/science.1198687.
17. Biron CA, Byron KS, Sullivan JL. 1989. Severe herpesvirus infections in an adolescent without natural killer cells. N Engl J Med 320:1731-1735. http://dx.doi.org/10.1056/NEJM198906293202605.
18. Orange JS. 2013. Natural killer cell deficiency. J Allergy Clin Immunol 132:515-525; quiz 526. http://dx.doi.org/10.1016/j.jaci.2013.07.020.
19. Fielding CA, Aicheler R, Stanton RJ, Wang EC, Han S, Seirafian S, Davies J, McSharry BP, Weekes MP, Antrobus PR, Prod'homme V, Blanchet FP, Sugrue D, Cuff S, Roberts D, Davison AJ, Lehner PJ, Wilkinson GW, Tomasec P. 2014. Two novel human cytomegalovirus NK cell evasion functions target MICA for lysosomal degradation. PLoS Pathog 10:e1004058. http://dx.doi.org/10.1371/journal.ppat.1004058.
20. Wilkinson GW, Tomasec P, Stanton RJ, Armstrong M, Prod'homme V, Aicheler R, McSharry BP, Rickards CR, Cochrane D, Llewellyn-Lacey S, Wang EC, Griffin CA, Davison AJ. 2008. Modulation of natural killer cells by human cytomegalovirus. J Clin Virol 41:206-212. http://dx.doi.org/10.1016/j.jcv.2007.10.027.
21. Stern-Ginossar N, Gur C, Biton M, Horwitz E, Elboim M, Stanietsky N, Mandelboim M, Mandelboim O. 2008. Human microRNAs regulate stress-induced immune responses mediated by the receptor NKG2D. Nat Immunol 9:1065-1073. http://dx.doi.org/10.1038/ni.1642.
22. Cosman D, Mullberg J, Sutherland CL, Chin W, Armitage R, Fanslow W, Kubin M, Chalupny NJ. 2001. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 14:123-133. http://dx.doi.org/10.1016/S1074-7613(01)00095-4.
23. Arnon TI, Achdout H, Levi O, Markel G, Saleh N, Katz G, Gazit R, Gonen-Gross T, Hanna J, Nahari E, Porgador A, Honigman A, Plachter B, Mevorach D, Wolf DG, Mandelboim O. 2005. Inhibition of the NKp30 activating receptor by pp65 of human cytomegalovirus. Nat Immunol 6:515-523.
24. Wills MR, Ashiru O, Reeves MB, Okecha G, Trowsdale J, Tomasec P, Wilkinson GW, Sinclair J, Sissons JG. 2005. Human cytomegalovirus encodes an MHC class I-like molecule (UL142) that functions to inhibit NK cell lysis. J Immunol 175:7457-7465. http://dx.doi.org/10.4049/jimmunol.175.11.7457.
25. Chalupny NJ, Rein-Weston A, Dosch S, Cosman D. 2006. Downregulation of the NKG2D ligand MICA by the human cytomegalovirus glycoprotein UL142. Biochem Biophys Res Commun 346:175-181. http://dx.doi.org/10.1016/j.bbrc.2006.05.092.
26. Smith W, Tomasec P, Aicheler R, Loewendorf A, Nemcovicova I, Wang EC, Stanton RJ, Macauley M, Norris P, Willen L, Ruckova E, Nomoto A, Schneider P, Hahn G, Zajonc DM, Ware CF, Wilkinson GW, Benedict CA. 2013. Human cytomegalovirus glycoprotein UL141 targets the TRAIL death receptors to thwart host innate antiviral defenses. Cell Host Microbe 13:324-335. http://dx.doi.org/10.1016/j.chom.2013.02.003.
27. Seidel E, Le VT, Bar-On Y, Tsukerman P, Enk J, Yamin R, Stein N, Schmiedel D, Oiknine Djian E, Weisblum Y, Tirosh B, Stastny P, Wolf DG, Hengel H, Mandelboim O. 2015. Dynamic coevolution of host and pathogen:HCMVdownregulates the prevalent allele MICA *008 to escape elimination by NK cells. Cell Rep 2015:pii:S2211-1247(15)00054-6. http://dx.doi.org/10.1016/j.celrep.2015.01.029.
28. Prod'homme V, Griffin C, Aicheler RJ, Wang EC, McSharry BP, Rickards CR, Stanton RJ, Borysiewicz LK, Lopez-Botet M, Wilkinson GW, Tomasec P. 2007. The human cytomegalovirus MHC class I homolog UL18 inhibits LIR-1+ but activates LIR-1-NKcells. J Immunol 178:4473-4481. http://dx.doi.org/10.4049/jimmunol.178.7.4473.
29. Prod'homme V, Tomasec P, Cunningham C, Lemberg MK, Stanton RJ, McSharry BP, Wang EC, Cuff S, Martoglio B, Davison AJ, Braud VM, Wilkinson GW. 2012. Human cytomegalovirus UL40 signal peptide regulates cell surface expression of the NK cell ligands HLA-E and gpUL18. J Immunol 188:2794-2804. http://dx.doi.org/10.4049/jimmunol.1102068.
30. Li T, Chen J, Cristea IM. 2013. Human cytomegalovirus tegument protein pUL83 inhibits IFI16-mediated DNA sensing for immune evasion. Cell Host Microbe 14:591-599. http://dx.doi.org/10.1016/j.chom.2013.10.007.
31. Stanton RJ, Prod'homme V, Purbhoo MA, Moore M, Aicheler RJ, Heinzmann M, Bailer SM, Haas J, Antrobus R, Weekes MP, Lehner PJ, Vojtesek B, Miners KL, Man S, Wilkie GS, Davison AJ, Wang EC, Tomasec P, Wilkinson GW. 2014. HCMV pUL135 remodels the actin cytoskeleton to impair immune recognition of infected cells. Cell Host Microbe 16:201-214. http://dx.doi.org/10.1016/j.chom.2014.07.005.
32. Sun JC, Lopez-Verges S, Kim CC, DeRisi JL, Lanier LL. 2011. NK cells and immune "memory". J Immunol 186:1891-1897. http://dx.doi.org/10.4049/jimmunol.1003035.
33. Farrell HE, Vally H, Lynch DM, Fleming P, Shellam GR, Scalzo AA, Davis-Poynter NJ. 1997. Inhibition of natural killer cells by a cytomegalovirus MHC class I homologue in vivo. Nature 386:510-514. http://dx.doi.org/10.1038/386510a0.
34. Beck S, Barrell BG. 1988. Human cytomegalovirus encodes a glycoprotein homologous toMHCclass-I antigens. Nature 331:269-272. http://dx.doi.org/10.1038/331269a0.
35. Leong CC, Chapman TL, Bjorkman PJ, Formankova D, Mocarski ES, Phillips JH, Lanier LL. 1998. Modulation of natural killer cell cytotoxicity in human cytomegalovirus infection: the role of endogenous class I major histocompatibility complex and a viral class I homolog. J Exp Med 187: 1681-1687. http://dx.doi.org/10.1084/jem.187.10.1681.
36. Kaiser BK, Pizarro JC, Kerns J, Strong RK. 2008. Structural basis for NKG2A/CD94 recognition of HLA-E. Proc Natl Acad SciUSA105:6696-6701. http://dx.doi.org/10.1073/pnas.0802736105.
37. Guma M, Budt M, Saez A, Brckalo T, Hengel H, Angulo A, Lopez-Botet M. 2006. Expansion of CD94/NKG2C+ NK cells in response to human cytomegalovirus-infected fibroblasts. Blood 107:3624-3631. http://dx.doi.org/10.1182/blood-2005-09-3682.
38. Guma M, Cabrera C, Erkizia I, Bofill M, Clotet B, Ruiz L, Lopez-Botet M. 2006. Human cytomegalovirus infection is associated with increased proportions of NK cells that express the CD94/NKG2C receptor in aviremic HIV-1-positive patients. J Infect Dis 194:38-41. http://dx.doi.org/10.1086/504719.
39. Lopez-Verges S, Milush JM, Schwartz BS, Pando MJ, Jarjoura J, York VA, Houchins JP, Miller S, Kang SM, Norris PJ, Nixon DF, Lanier LL. 2011. Expansion of a unique CD57(+)NKG2Chi natural killer cell subset during acute human cytomegalovirus infection. Proc Natl Acad Sci U S A 108:14725-14732. http://dx.doi.org/10.1073/pnas.1110900108.
40. Foley B, Cooley S, Verneris MR, Curtsinger J, Luo X, Waller EK, Anasetti C, Weisdorf D, Miller JS. 2012. Human cytomegalovirus (CMV)-induced memory-like NKG2C(+) NK cells are transplantable and expand in vivo in response to recipient CMV antigen. J Immunol 189:5082-5088. http://dx.doi.org/10.4049/jimmunol.1201964.
41. Wu Z, Sinzger C, Frascaroli G, Reichel J, Bayer C, Wang L, Schirmbeck R, Mertens T. 2013. Human cytomegalovirus-induced NKG2C(hi) CD57(hi) natural killer cells are effectors dependent on humoral antiviral immunity. J Virol 87:7717-7725. http://dx.doi.org/10.1128/JVI.01096-13.
42. Munoz-Cobo B, Gimenez E, Solano C, de la Camara R, Nieto J, Lopez J, Amat P, Garcia-Noblejas A, Navarro D. 2014. An evaluation of the role of NKG2C+ natural killer cells in protection from cytomegalovirus DNAemia early following allogeneic stem cell transplantation. J Med Virol 86:806-811. http://dx.doi.org/10.1002/jmv.23742.
43. Beziat V, Dalgard O, Asselah T, Halfon P, Bedossa P, Boudifa A, Hervier B, Theodorou I, Martinot M, Debre P, Bjorkstrom NK, Malmberg KJ, Marcellin P, Vieillard V. 2012. CMV drives clonal expansion of NKG2C+ NK cells expressing self-specific KIRs in chronic hepatitis patients. Eur J Immunol 42:447-457. http://dx.doi.org/10.1002/eji.201141826.
44. Costa-Garcia M, Vera A, Moraru M, Vilches C, Lopez-Botet M, Muntasell A. 2015. Antibody-mediated response of NKG2Cbright NK cells against human cytomegalovirus. J Immunol 194:2715-2724. http://dx.doi.org/10.4049/jimmunol.1402281.
45. Wu Z, Sinzger C, Reichel JJ, Just M, Mertens T. 2015. Natural killer cells can inhibit the transmission of human cytomegalovirus in cell culture by using mechanisms from innate and adaptive immune responses. J Virol 89:2906-2917. http://dx.doi.org/10.1128/JVI.03489-14.
46. Browne H, Churcher M, Minson T. 1992. Construction and characterization of a human cytomegalovirus mutant with the UL18 (class I homolog) gene deleted. J Virol 66:6784-6787.
47. Stanton RJ, Baluchova K, Dargan DJ, Cunningham C, Sheehy O, Seirafian S, McSharry BP, Neale ML, Davies JA, Tomasec P, Davison AJ, Wilkinson GW. 2010. Reconstruction of the complete human cytomegalovirus genome in a BAC reveals RL13 to be a potent inhibitor of replication. J Clin Invest 120:3191-3208. http://dx.doi.org/10.1172/JCI42955.
48. Stanton RJ, McSharry BP, Armstrong M, Tomasec P, Wilkinson GW. 2008. Re-engineering adenovirus vector systems to enable highthroughput analyses of gene function. Biotechniques 45:659-662, 664-658. http://dx.doi.org/10.2144/000112993.
49. Mason GM, Poole E, Sissons JG, Wills MR, Sinclair JH. 2012. Human cytomegalovirus latency alters the cellular secretome, inducing cluster of differentiation (CD)4+ T-cell migration and suppression of effector function. Proc Natl Acad Sci U S A 109:14538-14543. http://dx.doi.org/10.1073/pnas.1204836109.
50. Waller EC, Day E, Sissons JG, Wills MR. 2008. Dynamics of T cell memory in human cytomegalovirus infection. Med Microbiol Immunol 197:83-96. http://dx.doi.org/10.1007/s00430-008-0082-5.
51. Jackson SE, Mason GM, Okecha G, Sissons JG, Wills MR. 2014. Diverse specificities, phenotypes, and antiviral activities of cytomegalovirusspecific CD8+ T cells. J Virol 88:10894-10908. http://dx.doi.org/10.1128/JVI.01477-14.
52. Sinzger C, Knapp J, Plachter B, Schmidt K, Jahn G. 1997. Quantification of replication of clinical cytomegalovirus isolates in cultured endothelial cells and fibroblasts by a focus expansion assay. J Virol Methods 63:103-112. http://dx.doi.org/10.1016/S0166-0934(97)02082-X.
53. Tomasec P, Wang EC, Davison AJ, Vojtesek B, Armstrong M, Griffin C, McSharry BP, Morris RJ, Llewellyn-Lacey S, Rickards C, Nomoto A, Sinzger C, Wilkinson GW. 2005. Downregulation of natural killer cellactivating ligand CD155 by human cytomegalovirus UL141. Nat Immunol 6:181-188.
54. Cerboni C, Mousavi-Jazi M, Linde A, Soderstrom K, Brytting M, Wahren B, Karre K, Carbone E. 2000. Human cytomegalovirus straindependent changes in NK cell recognition of infected fibroblasts. J Immunol 164:4775-4782. http://dx.doi.org/10.4049/jimmunol.164.9.4775.
55. Nagel JE, Collins GD, Adler WH. 1981. Spontaneous or natural killer cytotoxicity of K562 erythroleukemic cells in normal patients. Cancer Res 41:2284-2288.
56. Fauriat C, Long EO, Ljunggren HG, Bryceson YT. 2010. Regulation of human NK-cell cytokine and chemokine production by target cell recognition. Blood 115:2167-2176. http://dx.doi.org/10.1182/blood-2009-08-238469.
57. Yang Z, Bjorkman PJ. 2008. Structure of UL18, a peptide-binding viralMHC mimic, bound to a host inhibitory receptor. Proc Natl Acad Sci U S A 105: 10095-10100. http://dx.doi.org/10.1073/pnas.0804551105.
58. Beziat V, Liu LL, Malmberg JA, Ivarsson MA, Sohlberg E, Bjorklund AT, Retiere C, Sverremark-Ekstrom E, Traherne J, Ljungman P, Schaffer M, Price DA, Trowsdale J, Michaelsson J, Ljunggren HG, Malmberg KJ. 2013. NK cell responses to cytomegalovirus infection lead to stable imprints in the human KIR repertoire and involve activating KIRs. Blood 121:2678-2688. http://dx.doi.org/10.1182/blood-2012-10-459545.
59. Cha TA, Tom E, Kemble GW, Duke GM, Mocarski ES, Spaete RR. 1996. Human cytomegalovirus clinical isolates carry at least 19 genes not found in laboratory strains. J Virol 70:78-83.
60. Dolan A, Cunningham C, Hector RD, Hassan-Walker AF, Lee L, Addison C, Dargan DJ, McGeoch DJ, Gatherer D, Emery VC, Griffiths PD, Sinzger C, McSharry BP, Wilkinson GW, Davison AJ. 2004. Genetic content of wild-type human cytomegalovirus. J Gen Virol 85:1301-1312. http://dx.doi.org/10.1099/vir.0.79888-0.
61. Prod'homme V, Sugrue DM, Stanton RJ, Nomoto A, Davies J, Rickards CR, Cochrane D, Moore M, Wilkinson GW, Tomasec P. 2010. Human cytomegalovirus UL141 promotes efficient downregulation of the natural killer cell activating ligand CD112. J Gen Virol 91:2034-2039. http://dx.doi.org/10.1099/vir.0.021931-0.
62. Magri G, Muntasell A, Romo N, Saez-Borderias A, Pende D, Geraghty DE, Hengel H, Angulo A, Moretta A, Lopez-Botet M. 2011. NKp46 and DNAM-1 NK-cell receptors drive the response to human cytomegalovirus-infected myeloid dendritic cells overcoming viral immune evasion strategies. Blood 117:848-856. http://dx.doi.org/10.1182/blood-2010-08-301374.
63. Vales-Gomez M, Shiroishi M, Maenaka K, Reyburn HT. 2005. Genetic variability of the major histocompatibility complex class I homologue encoded by human cytomegalovirus leads to differential binding to the inhibitory receptor ILT2. J Virol 79:2251-2260. http://dx.doi.org/10.1128/JVI.79.4.2251-2260.2005.
64. Cerboni C, Achour A, Warnmark A, Mousavi-Jazi M, Sandalova T, Hsu ML, Cosman D, Karre K, Carbone E. 2006. Spontaneous mutations in the human CMV HLA class I homologue UL18 affect its binding to the inhibitory receptor LIR-1/ILT2/CD85j. Eur J Immunol 36:732-741. http://dx.doi.org/10.1002/eji.200425220.
65. Sijmons S, Thys K, Mbong Ngwese M, Van Damme E, Dvorak J, Van Loock M, Li G, Tachezy R, Busson L, Aerssens J, Van Ranst M, Maes P. 13 May 2015. High-throughput analysis of human cytomegalovirus genome diversity highlights the widespread occurrence of gene-disrupting mutations and pervasive recombination. J Virol http://dx.doi.org/10.1128/JVI.00578-15.
66. Fadda L, Borhis G, Ahmed P, Cheent K, Pageon SV, Cazaly A, Stathopoulos S, Middleton D, Mulder A, Claas FH, Elliott T, Davis DM, Purbhoo MA, Khakoo SI. 2010. Peptide antagonism as a mechanism for NK cell activation. Proc Natl Acad Sci U S A 107:10160-10165. http://dx.doi.org/10.1073/pnas.0913745107.
67. Lopez-Botet M, Bellon T, Llano M, Navarro F, Garcia P, de Miguel M. 2000. Paired inhibitory and triggering NK cell receptors for HLA class I molecules. Hum Immunol 61:7-17. http://dx.doi.org/10.1016/S0198-8859(99)00161-5.
68. Guma M, Angulo A, Vilches C, Gomez-Lozano N, Malats N, Lopez-Botet M. 2004. Imprint of human cytomegalovirus infection on the NK cell receptor repertoire. Blood 104:3664-3671. http://dx.doi.org/10.1182/blood-2004-05-2058.
69. Sun JC, Beilke JN, Lanier LL. 2009. Adaptive immune features of natural killer cells. Nature 457:557-561. http://dx.doi.org/10.1038/nature07665.